Dravet syndrome is a rare disease and is a severe form of epilepsy that is a part of the group of diseases known as SCN1A-related seizure disorders. It occurs due to a mutation in the SCN1A gene, which is required for the proper function of brain cells.

Technavio’s analysts forecast the Global Dravet Syndrome Treatment Market to grow at a CAGR of 8.35% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the dravet syndrome treatment market. To calculate the market size, the report considers the revenue generated by the sale of drugs for the treatment of dravet syndrome across the globe.

The market is divided into the following segments based on geography:

Americas

APAC

EMEA

Technavio's report, dravet syndrome treatment market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

Biocodex

Epygenix Therapeutics

GW Pharmaceuticals

OPKO Health

Zogenix

Market driver

Rising number of strategic alliances

For a full, detailed list, view our report

Market challenge

Low awareness

For a full, detailed list, view our report

Market trend

Increased use of new generation drugs

For a full, detailed list, view our report

Key questions answered in this report

What will the market size be in 2022 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?